As many patients with underlying psychiatric disorders may be infected with COVID-19, and COVID-19-affected subjects may frequently experience a new onset of psychiatric manifestations, concomitant use of psychotropic medications and COVID-19 therapies is expected to be highly likely and raises concerns of clinically relevant drug interactions. In this setting, four major mechanisms responsible for drug interactions involving psychotropic agents and COVID-19 therapies may be identified: (1) pharmacokinetic drug–drug interactions mainly acting on cytochrome P450; (2) pharmacodynamic drug–drug interactions resulting in additive or synergistic toxicity; (3) drug–disease interactions according to stage and severity of the disease; and (4) pharmacogenetic issues associated with polymorphisms of cytochrome P450 isoenzymes. In this review, we summarise the available literature on relevant drug interactions between psychotropic agents and COVID-19 therapies, providing practical clinical recommendations and potential management strategies according to severity of illness and clinical scenario.
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies / Gatti M.; De Ponti F.; Pea F.. - In: CNS DRUGS. - ISSN 1172-7047. - ELETTRONICO. - 35:4(2021), pp. 345-384. [10.1007/s40263-021-00811-2]
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies
Gatti M.;De Ponti F.;Pea F.
2021
Abstract
As many patients with underlying psychiatric disorders may be infected with COVID-19, and COVID-19-affected subjects may frequently experience a new onset of psychiatric manifestations, concomitant use of psychotropic medications and COVID-19 therapies is expected to be highly likely and raises concerns of clinically relevant drug interactions. In this setting, four major mechanisms responsible for drug interactions involving psychotropic agents and COVID-19 therapies may be identified: (1) pharmacokinetic drug–drug interactions mainly acting on cytochrome P450; (2) pharmacodynamic drug–drug interactions resulting in additive or synergistic toxicity; (3) drug–disease interactions according to stage and severity of the disease; and (4) pharmacogenetic issues associated with polymorphisms of cytochrome P450 isoenzymes. In this review, we summarise the available literature on relevant drug interactions between psychotropic agents and COVID-19 therapies, providing practical clinical recommendations and potential management strategies according to severity of illness and clinical scenario.File | Dimensione | Formato | |
---|---|---|---|
40263_2021_Article_811.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione
1.68 MB
Formato
Adobe PDF
|
1.68 MB | Adobe PDF | Visualizza/Apri |
40263_2021_811_MOESM1_ESM.docx
accesso aperto
Tipo:
File Supplementare
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione
46.08 kB
Formato
Microsoft Word XML
|
46.08 kB | Microsoft Word XML | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.